Revelation Biosciences (NASDAQ:REVB) Releases Quarterly Earnings Results, Beats Expectations By $0.24 EPS

Revelation Biosciences (NASDAQ:REVB) issued its quarterly earnings data on Thursday. The company reported ($5.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.16) by $0.24, FiscalAI reports.

Revelation Biosciences Stock Performance

Shares of REVB stock traded up $0.33 during mid-day trading on Friday, reaching $3.89. 14,458 shares of the company were exchanged, compared to its average volume of 23,642. Revelation Biosciences has a fifty-two week low of $3.08 and a fifty-two week high of $40.60. The company has a market capitalization of $2.65 million, a P/E ratio of -0.09 and a beta of -0.13. The business’s 50 day simple moving average is $5.45 and its 200 day simple moving average is $7.79.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.